Logo

Genzyme Joins International Initiative to Help Develop Malaria Drugs

Oct 19, 2006
NEW YORK (GenomeWeb News) — Genzyme will join an international public/private initiative to develop malaria drugs, the company said yesterday.
 
The company will work with the Medicines for Malaria Venture, MIT’s Broad Institute, and Harvard University to develop treatments by identifying compounds that the company claims offer a new approach to treating the disease.
 
Genzyme said there are four discovery projects ongoing already, but did not disclose their specifics. The company added that any intellectual property stemming from the research will be made available to the MMV for drug development without royalties.  
 
MMV, a non-profit organization aimed at finding new antimalarial treatments, estimates that there are 300 million to 600 million new clinical cases of malaria each year.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.